

## The Enhancing Effect of $\gamma$ -Cyclodextrin Inclusion on $\gamma$ -Tocotrienol-dependent Negative Growth Control of Mesothelioma Cells in a Xenograft Model

<sup>1</sup>, \*Yano T, <sup>1</sup>Sato A, <sup>1</sup>Sekine M, <sup>2</sup>Kashiwagi K, <sup>1</sup>Ota M.

<sup>1</sup>Research Group of Nutritional Sciences, Faculty of Life Sciences, Toyo University, Gunma, 374-0193, Japan; <sup>2</sup>Department of Experimental Pathology, Yokohama City University Graduate School of Medicine, Kanagawa, 315-0345, Japan

\*Corresponding Author: Tomohiro Yano, PhD, Professor, Research Group of Nutritional Sciences, Faculty of Life Sciences, Toyo University, Gunma, 374-0193, Japan. Phone number: +81-274-82-9143

Submission date: October 19, 2011; Acceptance date: December 11, 2011; Publication date: December 30, 2011

### **ABSTRACT**

**Background:** Malignant mesothelioma is an aggressive cancer with no effective treatment options. Of phytochemicals, tocotrienol (T3), a member of vitamin E, is one of the most potent anti-mesothelioma agents, but the effectiveness *in vivo* is quite limited, due to its low bioavailability. In this study, we investigated if the oral treatment of  $\gamma$ -T3 inclusion with  $\gamma$ -cyclodextrin (CD) could improve the bioavailability and anticancer activity of the T3.

**Findings:** Using nude mice bearing MSTO-211H cells (a human malignant mesothelioma cell line), the effect of  $\gamma$ -T3 inclusion with  $\gamma$ -CD on  $\gamma$ -T3 level in tumor tissues, tumor growth, and its related mRNA levels were examined. The difference of tumor growth between the two groups had no statistical significance, but the latter showed a lower tendency compared with the former. In linked with this observation, the level of vascular endothelial growth factor mRNA required for *in vivo* tumor growth in  $\gamma$ -T3 inclusion with  $\gamma$ -CD group was lower than that in  $\gamma$ -T3 group, on the contrary, the level of  $\gamma$ -T3 level showed an opposite tendency.

**Conclusion:** Our study demonstrated that the bioavailability of  $\gamma$ -T3 was improved by an oral administration of a novel  $\gamma$ -T3 inclusion complex with CD. Furthermore, the improvement of

the bioavailability contributed to the increase of anticancer activity of  $\gamma$ -T3 *in vivo*.

**Key words:** Anti-cancer agent, bioavailability, cyclodextrin, mesothelioma, tocotrienol.